The results of the study were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, which was held online on 4–8 June 2021.

The community oncology practice, Texas Oncology, elected to increase the use of biosimilars in 2020. They started with rituximab in July 2020, followed by bevacizumab in September 2020 and finally trastuzumab in October 2020. In order to facilitate the substitution educational materials were created for both patients and clinical staff. A central pharmacy team then reviewed all new orders and substituted a biosimilar for the brand-name biological unless a payer insisted on the originator drug or a biosimilar not in the practice formulary. The pharmacists, upon consultation with the physician, then substituted a biosimilar for the brand-name biological.

Between January and December 2020, the practice was able to increase its use of biosimilars from 5% to 80% for rituximab, 9% to 88% for bevacizumab and 8% to 74% for trastuzumab. Based on the average market-based price for a 70 kg patient, the potential savings per administration were calculated to be US$550 for bevacizumab, US$850 for trastuzumab and US$1,400 for rituximab. In one month alone, this project dramatically reduced costs by US$4 million or 21% by substituting expensive brand-name biologicals with more cost-effective biosimilars. The authors also added that ‘additional savings can be realized with the use of biosimilar multi-dose vials vs single dose vials’.

The authors concluded that substituting biosimilars for brand-name drugs in a community oncology practice ‘leads to substantial cost savings’ and that this has ‘real implications in controlling the total cost of care’.

Conflict of interest
The authors of the abstract [1] did not provide any conflict-of-interest statement.

Editor’s comment
It should be noted that data of the study presented in this article were published as an abstract and presented at a conference. These data and conclusions should be considered as preliminary until published in a peer-reviewed journal.

Readers interested to learn more about pharmacist-driven substitution of biosimilars are invited to visit www.gabi-journal.net to view the following manuscripts published in GaBI Journal:

Global policies on pharmacy-mediated substitution of biosimilars: a summary

Pharmacy-mediated substitution of biosimilars – a global survey benchmarking country substitution policies

GaBI Journal is indexed in Embase, Scopus, Emerging Sources Citation Index and more.

Readers interested in contributing a research or perspective paper to GaBI Journal – an independent, peer reviewed academic journal – please send us your submission here.

GaBI Journal Citation Impact
1.9 – CiteScore 2020 (calculated on 5 May 2021)
1.9 – CiteScoreTracker 2021 (Last updated on 4 August 2021)

Submit a manuscript to GaBI Journal

Related articles
Biosimilar substitution in Europe

Saving money and building trust in biosimilars

  
Reference
1. Wilfong LS, Dave N, Garey JS, et al. A successful model of biosimilar adoption in a community oncology practice. Abstract presented at: American Society of Clinical Oncology (ASCO) Annual Meeting. Online, 4–8 June 2021; Abstract no. 6514.

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2021 Pro Pharma Communications International. All Rights Reserved.